Published in Pharma Investments, Ventures and Law Weekly, July 25th, 2004
Macugen is a non-antisense, investigational treatment for ophthalmic diseases, including wet AMD and diabetic macular edema.
In 2002, Eyetech licensed from Isis specific patents necessary to develop, manufacture, and commercialize Macugen. Under the terms of the agreement, Isis may earn additional milestone and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.